Please wait a minute...
ZJUS-B
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2010, Vol. 11 Issue (1): 1-9    DOI: 10.1631/jzus.B0900295
Biomedicine     
Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy
Ching-hung LIN, Huang-chun LIEN, Fu-chang HU, Yen-shen LU, Sung-hsin KUO, Ling-chu WU, San-lin YOU, Ann-lii CHENG, King-jen CHANG, Chiun-sheng HUANG
Department of Oncology, National Taiwan University Hospital, Taiwan, Taipei 10016; Department of Pathology, National Taiwan University Hospital, Taiwan, Taipei 10016; National Center of Excellence for General Clinical Trial and Research, National Taiwan University Hospital, Taiwan, Taipei 10016; Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taiwan, Taipei 10055; Department of Surgery, National Taiwan University Hospital, Taiwan, Taipei 10016
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Objective: To compare the prognostic prediction between dichotomized and fractionated evaluations of hormone receptor expressions. Methods: Patients with stages I鈥揑II breast cancers, who received adjuvant tamoxifen, were enrolled. The expression of estrogen receptor (ER) and progesterone receptor (PR) was evaluated by immunohistochemistry (IHC). A fractionated score (F score), the percentage of positive-staining nuclei (0=none, 1=1%鈥?0%, 2=11%鈥?0%, 3=31%鈥?0%, 4=51%鈥?0%, and 5=71%鈥?00%), was assigned to each case. The dichotomized scoring method defines an F score >1 as positive. The prognostic values of both scores were compared by multiple Cox鈥檚 proportional hazard models of disease-free survival (DFS) and overall survival (OS). Results: Four hundred and sixteen patients with a median follow-up of 78.0 months were included. F scores for ER and PR correlated directly with DFS and OS. Although both the dichotomized and fractionated ER and PR scores were significantly associated with DFS and OS in univariate analyses, only fractionated ER and PR scores remained as independent prognostic factors of DFS and OS in the final multiple Cox鈥檚 proportional hazard models. Conclusion: Fractionated IHC hormone receptor expression evaluation enhances the prognostic prediction compared with a dichotomized assessment.

Key words： Breast cancer      Fractionated evaluation      Estrogen receptor      Progesterone receptor     
Received: 24 September 2009      Published: 01 January 2010
CLC:  R75  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
King-jen CHANG
Chiun-sheng HUANG
Ching-hung LIN
Huang-chun LIEN
Fu-chang HU
Yen-shen LU
Sung-hsin KUO
Ling-chu WU
San-lin YOU
Ann-lii CHENG
Cite this article:

Ching-hung LIN, Huang-chun LIEN, Fu-chang HU, Yen-shen LU, Sung-hsin KUO, Ling-chu WU, San-lin YOU, Ann-lii CHENG, King-jen CHANG, Chiun-sheng HUANG. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2010, 11(1): 1-9.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.B0900295     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2010/V11/I1/1

[1] Shi-chong Liao, Jin-xin Li, Li Yu, Sheng-rong Sun. Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(4): 334-342.
[2] Shu-min Liu, Shi-yi Ou, Hui-hua Huang. Green tea polyphenols induce cell death in breast cancer MCF-7 cells through induction of cell cycle arrest and mitochondrial-mediated apoptosis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(2): 89-98.
[3] Ming Zhao, Xian-feng Ding, Jian-yu Shen, Xi-ping Zhang, Xiao-wen Ding, Bin Xu. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(1): 15-26.
[4] Chun-xi Wang, Shu-li Guo, Li-na Han. Successful treatment of accessory breast cancer with endocrine therapy[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(1): 70-75.
[5] Zhao-ji Liu, Gregg L. Semenza, Hua-feng Zhang. Hypoxia-inducible factor 1 and breast cancer metastasis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 32-43.
[6] Xinguo Jiang. Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 44-45.
[7] Hui-xin Liu, Xiao-li Li, Chen-fang Dong. Epigenetic and metabolic regulation of breast cancer stem cells[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 10-17.
[8] Wei Wang, Yun-ping Luo. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 18-31.
[9] Jie Ding, Hui Xu, Xiang Yin, Fu-rong Zhang, Xiao-ping Pan, Yi-an Gu, Jun-zhu Chen, Xiao-gang Guo. Estrogen receptor α gene PvuII polymorphism and coronary artery disease: a meta-analysis of 21 studies[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(3): 243-255.
[10] Xinguo Jiang. Harnessing the immune system for the treatment of breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(1): 1-15.
[11] Sheereen Tarannum, Zarina Arif, Khursheed Alam. Binding of circulating autoantibodies in breast cancer to native and peroxynitrite-modified RNA[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2013, 14(1): 40-46.
[12] Lin-run Wang, Guo-bing Zhang, Jian Chen, Jun Li, Ming-wei Li, Nong Xu, Yang Wang, Jian-zhong Shentu. RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2011, 12(3): 174-179.
[13] Yi ZHENG, Jing ZHANG, Zhen-zhen XU,Jian-ming SHENG, Xiao-chen ZHANG, Hao-hao WANG, Xiao-dong TENG, Xiao-jiao LIU, Jiang CAO, Li-song TENG. Quantitative profiles of the mRNAs of ER-α and its novel variant ER-α36 in breast cancers and matched normal tissues[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2010, 11(2): 144-150.
[14] Shan-zhi GU, Xin-han ZHAO, Ling-xiao ZHANG, Li LI, Zhi-yu WANG, Min MENG, Gai-li AN. Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2009, 10(3): 159-167.
[15] Xiao-cao SHEN, Cai-xiao GU, Yi-qing QIU, Chuan-jun DU, Yan-biao FU, Jian-jun WU. Estrogen receptor expression in adrenocortical carcinoma[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2009, 10(1): 1-6.